FDA label
What is Arynta used for?
Arynta contains lisdexamfetamine. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “ARYNTA is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older; Moderate to severe binge eating disorder (BED) in adults; The use of ARYNTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than p...”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Arynta?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Arynta, solution
Indications and Usage, quoted from the label by Azurity Pharmaceuticals, Inc. (NDA219847). Cross-references to other label sections are left out.
ARYNTA is indicated for the treatment of:
- Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older
- Moderate to severe binge eating disorder (BED) in adults.
Limitations of Use:
- The use of ARYNTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
- ARYNTA is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of ARYNTA for the treatment of obesity have not been established.
Source: DailyMed label, set id 71cdfc97-96af-4378-a44a-6d5d77e7d6b7, version 4, effective July 30, 2025. NDC 24338-019, one of 5 listings for this product.
Questions
What is Arynta used for?
The FDA label says: “ARYNTA is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older; Moderate to severe binge eating disorder (BED) in adults; The use of ARYNTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than p...”
What drug class is Arynta?
FDA lists lisdexamfetamine in the Central Nervous System Stimulant established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Arynta
- Is Arynta a controlled substance?Schedule II
- Generic for AryntaFDA Orange Book
- What is Lisdexamfetamine used for?FDA label uses
- Is Lisdexamfetamine a controlled substance?Schedule II
- Generic for VyvanseFDA Orange Book
- Central Nervous System Stimulants listFDA drug class
- NDC 24338-019Arynta NDC record
- NDC 24338-103Arynta NDC record
- NDC 24338-109Arynta NDC record
- Schedule II drugs listDEA schedule